At the national two sessions this year, the topic of cancer prevention and control became one of the hot topics, and many representatives and members made suggestions on the early screening and prevention of cancer.
"What are the symptoms of early tumors? No symptoms, no typical symptoms." Wang Guiqi, member of the CPPCC National Committee and director of the endoscopy department of the Cancer Hospital of the Chinese Academy of Medical Sciences, said at the second "committee channel" of the fifth session of the 13th CPPCC National Committee on March 7 that most people go to the hospital only after they have symptoms such as fever, inability to eat and always uncomfortable. However, once malignant tumors have obvious symptoms, they are almost in the middle and late stage. Therefore, when we think we are very healthy, we should also carry out targeted early tumor screening.
Wang Guiqi said that there has never been a "sudden tumor". Like the high incidence of esophageal cancer, gastric cancer and colorectal cancer in China, it usually takes 10 to 15 years from normal to advanced cancer. At present, China's screening and early diagnosis technology can find early cancer and precancerous lesions, and then treat or even cure these diseases through super minimally invasive technology under the condition of preserving human organs and ensuring postoperative quality of life.Early screening for cancer is expected to
significantly improve survival
Gu Jin, deputy to the National People's Congress and President of Shougang Hospital of Peking University, suggested strengthening the compliance and qualification certification of early cancer screening and giving play to the "funnel" role of home screening; Ji Jiafu, President of the CPPCC National Committee and Peking University Cancer Hospital, said early screening and diagnosis are conducive to early intervention in cancer treatment, reducing incidence rate and mortality and improving survival rate.
According to the data of the National Cancer Registry Center, more than 80% of the patients with lung cancer, breast cancer, liver cancer and colorectal cancer are mostly in the middle and late stages. They not only miss the best time to cure, but also cause huge medical expenses to the society.
It is understood that the benefit improvement of patients with advanced tumors is calculated in months. If a new drug can significantly improve the survival time of patients for 8 months and 10 months, it will be a heavy drug all over the world. However, if cancer can be found early, the improvement of patients' survival can be calculated in years, and it may even be cured. This is a big difference.
In this regard, Zhou Jun, CEO of Herui gene, said in an interview with the reporter of Securities Daily that in recent years, new treatment methods have been introduced in cancer clinic, but they all face a problem, that is, the tumor progresses to the middle and advanced stage. Even if it is treated through some innovative therapies, the benefits of patients are very limited, but at this time, the burden of medical resources of patients' families and the whole society is very large.
"As many doctors from the clinical front line have pointed out, early screening and prevention and control is the most effective and economical cancer solution. It will be better to advance the time of cancer detection, both clinically and economically." Zhou Jun told reporters.
Accelerate the implementation of new technologies and products
With the growth of clinical demand and the progress of technology, China's cancer early screening market has developed rapidly.
"Technically, domestic and foreign enterprises are in the same starting line and have their own advantages; China has its own uniqueness in some directions such as clinical resources." Zhou Jun told reporters that the application of NGS technology enables enterprises to early detect tumors in a broader dimension and more complex level. The application of this technology has opened up a new direction for the early prevention and treatment of tumors. This is an intersection of clinical needs and technological progress.
"At present, the cancer early screening market is in a critical stage of development, and new technologies and products are rapidly applied to this industry. Of course, many products still need larger-scale data verification, and the technology is constantly iterative." Zhou Jun said, "at this stage, we need to work together to do market education, cooperate with upstream and downstream to do basic scientific research and technology in-depth development, innovative technology and innovative commercialization exploration."
Gu Jin, deputy to the National People's Congress and President of Shougang Hospital of Peking University, stressed that the above tests must have the qualification certified by the national health administrative department.
Nuohui health stakeholders told our reporter that when consumers choose products for early screening and consumer self-test, they need to pay attention to whether the products have the qualification approved by the State Food and drug administration; The principles given by the center for device review: verification of prospective clinical trials, negative predictive value and sensitivity reaching high standards, etc.
Whether cancer early screening products are included in medical insurance reimbursement is the focus of the industry. According to media reports, at this year's two sessions, Hua Yawei, a member of the National Committee of the Chinese people's Political Consultative Conference, suggested to improve the supporting policies related to early screening. These include the inclusion of cancer early screening projects and products into the payment catalogue of medical insurance or commercial insurance, especially the cancer screening regularly participated by high-risk groups every year into the payment scope of outpatient medical insurance, so that more people can be screened and afford it, and improve the rate of early diagnosis and treatment.
"There are great differences in the clinical business environment between China and the West. In foreign countries, commercial insurance is the core of the medical business chain; but in China, the logic of China's medical insurance is wide coverage and basic insurance, while the commercial insurance corresponding to new technologies and new products needs to be further developed. Therefore, the commercialization of early screening is inseparable from the development of domestic commercial insurance, and both sides need to become the development of the same ecology Partners, step by step. " Zhou Jun told the reporter of Securities Daily.
Source: Securities Daily
https://new.qq.com/rain/a/20220308A0BB4100
